胃泌素受体拮抗剂对大肠癌肝转移的疗效观察  

EFFECT OF GASTRIN RECEPTOR ANTAGONIST ON COLON CANCER PATIENTS WITH LIVER METASTASIS

作　　者：谢尚奎 吴印爱 刘献棠 何双梧 李锋 

机构地区：[1]广州市梅花园157中心医院普外科,广州510510

出　　处：《中国普外基础与临床杂志》2000年第3期159-160,共2页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的　观察胃泌素拮抗剂对大肠癌肝转移患者的治疗效果。方法　对照组 3 8例常规化疗 ;治疗组 46例除常规化疗外同时服用胃泌素受体拮抗剂丙谷胺 12 0 0mg/d。两组患者每月定期随访 1次。 结果　对照组患者 1年内肝脏转移癌最大径增加 8.1± 2 .2cm ,死亡率为 5 5 .3 % ( 2 1/3 8) ;治疗组患者肝脏转移癌 1年内最大径增加 3 .5± 1.2cm ,死亡率为 2 1.7% ( 10 /46) ,均明显低于对照组 (P <0 .0 1)。结论　用胃泌素受体拮抗剂对大肠癌肝转移患者进行治疗 ,可以延缓肿瘤生长 ,延长患者生存时间 ,降低患者死亡率。Objective To study the effect of gastrin receptor antagonist on large intestine cancer patients with liver metastatic. Methods Thirty eight patients received chemotherapy in control group, in therapy group 46 patients received chemotherapy and gastrin receptor antagonist pruglumide 1 200 mg/day. Follow-up was done each month in two groups. Results In control group, liver metastatic cancer increased 8.1±2.2 cm, 1-year mortality was 55.3% (21/38), and in therapy group, liver metastatic cancer increased 3.5±1.2 cm, the mortality was 21.7% (10/46), which was significantly lower than that in control group (P<0.01). Conclusion Gastrin receptor antagonist can delay cancer proliferation, prolong survival time and decrease death rate of colon cancer patients with liver metastasis.

关 键 词：大肠肿瘤 肝转移 胃泌素受体拮抗剂 

分 类 号：R735.34[医药卫生—肿瘤]